Skip to main content
Log in

When good cholesterol turns bad: The evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein

  • Invited Commentary
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Duffy D, Rader DJ: Emerging therapies targeting highdensity lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113:1140–1150.

    Article  PubMed  Google Scholar 

  2. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  3. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.

    Article  PubMed  CAS  Google Scholar 

  4. Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160–167.

    Article  PubMed  CAS  Google Scholar 

  5. Okamoto H, Yonemori F, Wakitani K, et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203–207.

    Article  PubMed  CAS  Google Scholar 

  6. Yvan-Charvet L, Matsuura F, Wang N, et al.: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132–1138.

    Article  PubMed  CAS  Google Scholar 

  7. Oram JF, Heinecke JW: ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005, 85:1343–1372.

    Article  PubMed  CAS  Google Scholar 

  8. Chait A, Han CY, Oram JF, Heinecke JW: Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005, 46:389–403.

    Article  PubMed  CAS  Google Scholar 

  9. Shao B, Oda MN, Oram JF, Heinecke JW: Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006, 21:322–328.

    Article  PubMed  Google Scholar 

  10. Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032–13037.

    Article  PubMed  CAS  Google Scholar 

  11. Vaisar T, Pennathur S, Green PS, et al.: Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007, 117:746–756.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John F. Oram.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oram, J.F., Heinecke, J.W. When good cholesterol turns bad: The evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Curr Atheroscler Rep 9, 425–427 (2007). https://doi.org/10.1007/s11883-007-0055-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-007-0055-y

Keywords

Navigation